Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2017

01-02-2017 | Original Article

Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma

Authors: Shinya Morita, Yuji Nakamaru, Akihiro Homma, Shinichiro Yasukawa, Hiromitsu Hatakeyama, Tomohiro Sakashita, Satoshi Kano, Atsushi Fukuda, Satoshi Fukuda

Published in: International Journal of Clinical Oncology | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to investigate the expression of p53, p16, cyclin D1, epidermal growth factor receptor (EGFR) and Notch1 in temporal bone squamous cell carcinoma (TBSCC) tissue samples by immunohistochemistry (IHC), and to evaluate the association between these biomarkers and clinicopathological features.

Methods

We performed a retrospective, single-institution review of 30 TBSCC patients treated with curative intent between April 2006 and March 2015. All tissue samples were obtained from pretreatment biopsy specimens or surgical specimens and using IHC staining.

Results

Ten patients were categorized as T1, seven as T2, five as T3 and eight as T4. Nine patients had clinically positive lymph node metastasis. The positive expression of p53 and EGFR was significantly associated with T classification (P = 0.042 and P = 0.0039). EGFR expression was significantly more frequent in patients with positive lymph node metastasis compared with patients without node involvement (P = 0.017). In the analysis of the association between protein expression by IHC staining and prognosis, the positive expression of EGFR and Notch1 was significantly correlated with poor survival outcomes in TBSCC (P = 0.015 and P = 0.025)

Conclusion

Overexpression of p53 and EGFR may be valuable biomarkers for identifying individuals at high risk of developing tumors in TBSCC. Furthermore, the positive expression of EGFR was significantly associated with poor survival outcome. Anti-EGFR therapy has potential for use as the treatment modality of choice for advanced-stage TBSCC as well as other head and neck squamous cell carcinomas.
Literature
1.
Yin M, Ishikawa K, Honda K et al (2006) Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx 33:251–257CrossRefPubMed
2.
Moody SA, Hirsch BE, Myers EN (2000) Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol 21:582–588PubMed
3.
Ito M, Hatano M, Yoshizaki T (2009) Prognostic factors for squamous cell carcinoma of the temporal bone: extensive bone involvement or extensive soft tissue involvement? Acta Otolaryngol 129:1313–1319CrossRefPubMed
4.
Kropveld A, Slootweg PJ, van Mansfeld AD et al (1996) Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 78:991–997CrossRefPubMed
5.
Shin DM, Lee JS, Lippman SM et al (1996) p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88:519–529CrossRefPubMed
6.
Gasparini G, Bevilacqua P, Bonoldi E et al (1995) Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1:1375–1383PubMed
7.
Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed
8.
Agrawal N, Frederick MJ, Pickering CR et al (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154–1157CrossRefPubMedPubMedCentral
9.
Gursel DB, Berry N, Boockvar JA (2012) The contribution of Notch signaling to glioblastoma via activation of cancer stem cell self-renewal: the role of the endothelial network. Neurosurgery 70:N19–N21CrossRefPubMed
10.
Yabuuchi S, Pai SG, Campbell NR et al (2013) Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335:41–51CrossRefPubMedPubMedCentral
11.
Lee HJ, Kang YH, Lee JS et al (2015) Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health 15:153CrossRefPubMedPubMedCentral
12.
Sato-Kuwabara Y, Fregnani JH, Jampietro J et al (2016) Comparative analysis of basaloid and conventional squamous cell carcinomas of the esophagus: prognostic relevance of clinicopathological features and protein expression. Tumour Biol 37:6691–6699CrossRefPubMed
13.
Sakashita T, Homma A, Suzuki S et al (2013) Prognostic value of cyclin D1 expression in tumor-free surgical margins in head and neck squamous cell carcinomas. Acta Otolaryngol 133:984–991CrossRefPubMed
14.
Chu D, Zhou Y, Zhang Z et al (2011) Notch1 expression, which is related to p65 status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res 17:5686–5694CrossRefPubMed
15.
Takenaka Y, Cho H, Nakahara S et al (2015) Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: a meta-analysis. Head Neck 37:1073–1080CrossRefPubMed
16.
Sweeny L, Dean NR, Magnuson JS et al (2012) EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 34:681–686CrossRefPubMed
17.
18.
Marchetti P, Cannita K, Ricevuto E et al (2003) Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol 14:704–708CrossRefPubMed
19.
Karpathiou G, Monaya A, Forest F et al (2016) p16 and p53 expression status in head and neck squamous cell carcinoma: a correlation with histological, histoprognostic and clinical parameters. Pathology 48:341–348CrossRefPubMed
20.
Zambetti GP (2007) The p53 mutation “gradient effect” and its clinical implications. J Cell Physiol 213:370–373CrossRefPubMed
21.
Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26CrossRefPubMed
22.
Nyrop M, Grontved A (2002) Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg 128:834–837CrossRefPubMed
23.
Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–1354CrossRefPubMed
24.
Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584PubMed
25.
Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamics properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30:255–268CrossRefPubMed
26.
Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMed
27.
28.
Shao H, Huang Q, Liu ZJ (2012) Targeting notch signaling for cancer therapeutic intervention. Adv Pharmacol 65:191–234CrossRefPubMed
29.
Ai Q, Ma X, Huang Q et al (2012) High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One 7:e35022CrossRefPubMedPubMedCentral
30.
Zhou L, Zhang N, Song W et al (2013) The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. PLoS One 8:e57382CrossRefPubMedPubMedCentral
31.
Lin JT, Chen MK, Yeh KT et al (2010) Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann Surg Oncol 17:2976–2983CrossRefPubMed
32.
Valgardsdottir R, Tryggvadottir L, Steinarsdottir M et al (1997) Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 105:121–130CrossRefPubMed
Metadata
Title
Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma
Authors
Shinya Morita
Yuji Nakamaru
Akihiro Homma
Shinichiro Yasukawa
Hiromitsu Hatakeyama
Tomohiro Sakashita
Satoshi Kano
Atsushi Fukuda
Satoshi Fukuda
Publication date
01-02-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1026-5

Other articles of this Issue 1/2017

International Journal of Clinical Oncology 1/2017 Go to the issue

Original Article

Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy

Original Article

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy

Original Article

A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

Original Article

The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy

Original Article

Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors

Original Article

Estimation of Physiologic Ability and Surgical Stress (E-PASS) versus modified E-PASS for prediction of postoperative complications in elderly patients who undergo gastrectomy for gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits